Clinical trials update from the European Society of Cardiology Meeting 2010: SHIFT, PEARL-HF, STAR-heart, and HEBE-III

European Journal of Heart Failure

Volumn 12, Issue 11, 2010, Pages 1261-1264

  Cleland, John G F ^a   Coletta, Alison P ^a   Torabi, Azam ^a   Ahmed, Daniyal ^a   Clark, Andrew L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Heart failure; Randomized controlled trials

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ERYTHROPOIETIN; IVABRADINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; POTASSIUM DERIVATIVE; RLY 5016; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ANEMIA; BRADYCARDIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; MEDICAL SOCIETY; MORTALITY; OPTIMAL DRUG DOSE; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; SINGLE DRUG DOSE; SINUS RHYTHM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VISUAL DISORDER; VOMITING;

ADRENERGIC BETA-ANTAGONISTS; BENZAZEPINES; CLINICAL TRIALS AS TOPIC; COMORBIDITY; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; HEART FAILURE; HEMATINICS; HUMANS; HYPERKALEMIA; MYOCARDIAL INFARCTION; POLYMERS; RENAL INSUFFICIENCY; STEM CELL TRANSPLANTATION;

EID: 77958599548     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq186     Document Type: Conference Paper

References (20)

1. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL Investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-821.
2. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L. Rationale and design of a randomized double-blind placebo-controlled outcome trial of ivabra-dine in chronic heart failure: the Systolic heart failure treatment with the I(f) inhibitor ivabradine trial (SHIFT). Eur J Heart Fail 2010;12:75-81.
3. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, Van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
4. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, on behalf of the SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised controlled study. Lancet 2010;376:875-885.
5. Adamopoulos C, Ahmed A, Fay R, Angioi M, Filippatos G, Vincent J, Pitt B, Zannad F, the EPHESUS Investigators. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Fail 2009;11:1099-1105.
6. Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Eng J Med 1999;341:709-717.
7. Boccanelli A, Mureddu GF, Ciacciatore G, Clemenza F, Di Lenarda A, Gavazzi A, Porcu M, Latini R, Lucci D, Maggioni AP, Masson S, Vanasia M, De Simone G, on behalf of the AREA IN-CHF Investigators. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail 2009;11:68-76.
8. Zannad F, McMurray JJV, Drexler H, Krum H, Van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. Rationale and design of the eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF). Eur J Heart Fail 2010;12:617-622.
9. Schachinger V, Erbs S, Elasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM, REPAIR-AMI Investigators. Intracoronary bone marrow derived progenitor cells in acute myocardial infarction. N Eng J Med 2006;355:1210-1221.
10. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taradsrud E, Grogaard HK, Bjornerheim R, Brekke M, Muller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Eng J Med 2006;355:1199-1209.
11. Meyer GP, Wlooert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, Hecker H, Schaefer A, Arseniev L, Hertenstein B, Ganser A, Drexler H. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months follow-up data from the randomized controlled BOOST trial. Circulation 2006;113: 1287-1294.
12. Cleland JGF, Coletta AP, Abdellah AT, Cullington D, Clark AL, Rigby AS. Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE, and stem cell therapy. Eur J Heart Fail 2008;10:102-108.
13. Strauer BE, Yousef M, Schannwell CM. The acute and long term effects of intra-coronary stem cell transplantation in 191 patients with chronic heart failure: the STAR-heart study. Eur J Heart Fail 2010;12:721-729.
14. Domian IJ, Buikema JW, De Boer RA, Van Der Meer P. Stem cells in heart failure. Eur J Heart Fail 2010;12:642-644.
15. McMurray JJV, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tenders M, Van Vedhuisen DJ, Wasserman SM, Young JB, on behalf of the RED-HF Committees and Investigators. Design of the reduction in events with darbepoietin alfa in heart failure (RED-HF): a phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009;11:795-801.
16. Lipsic E, Schoemaker RG, Van Der Meer P, Voors AA, Van Veldhuisen DJ, Van Gilst WH. Protective effects of erythropoietin in cardiac ischaemia: from bench to bedside. J Am Coll Cardiol 2006;48:2161-2167.
17. Lipsic E, Westenbrink BD, Van Der Meer P, Van Der Harst P, Voors AA, Van Veldhuisen DJ, Schoemaker RG, Van Gilst WH. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haema-tocrit. Eur J Heart Fail 2008;10:22-29.
18. Lipsic E, Van Der Meer P, Voors AA, Westenbrink BD, Van den Huevel AF, De Boer HC, Schoemaker RG, Van Gilst WH, Zijlstra F, Van Veldhuisen DJ. A single bolus dose of a long acting erythropoietin analogue darbepoietin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006;20:135-141.
19. Belonje AM, Voors AA, Van Gilst WH, Anker SD, Slart RH, Tio RA, Zijlstra F, Van Veldhuisen DJ, HEBE-III investigators. Effects of erythropoietin after an acute myocardial infarction: rationale and design of a prospective randomized clinical trial (HEBE-II). Am Heart J 2008;155:817-822.
20. Voors AA, Belonje AM, Zijlstra F, Hillege H, Anker SD, Slart RH, Tio RA, van't Hof A, Jukema JW, Peels HO, Henriques JP, Ten Berg JM, Vos J, Van Gilst WH, Van Veldhuisen DJ, on behalf of the HEBE-III investigators. A single dose of ery-thropoietin in ST-elevation myocardial infarction. Eur Heart J 2010 Aug 29 [Epub ahead of print].